To kick things off, we'll set the stage on what defines non-muscle invasive bladder cancer and how we triage patient ...

Pharma titans Merck, Pfizer and Astellas Pharma are delivering an "enormous new hope" for patients with an aggressive form of ...

The potential of moving the combination to the earlier MIBC setting significantly increases the Padcev market.

Enfortumab vedotin and pembrolizumab with surgery significantly improve outcomes in cisplatin-ineligible MIBC patients, ...

Patients with muscle-invasive bladder cancer who test positive for circulating tumor (ct)DNA after surgery to remove the ...

The combination of Merck’s Keytruda and Pfizer and Astellas’ Padcev reduced patients' risk of death by a whopping 50% when used before and after bladder removal surgery in those with MIBC who are not ...

Pfizer and Japanese firm Astellas' drug Padcev, combined with Merck's Keytruda, lowered the risk of tumor recurrence, ...

The National Institute for Health and Care Excellence (NICE) published draft guidance recommending avelumab (Bavencio, Merck Serono) for the treatment of certain forms of bladder cancer. Adults with ...

This is the first meta-analysis comparing the overall survival of patients with limited-stage small cell bladder cancer who underwent radical surgery with platinum-based perioperative chemotherapy vs ...

Results presented by AstraZeneca from its phase 3 trial of Imfinzi in patients with high-risk, non-muscle invasive bladder ...